Vancouver’s CereCura Nanotherapeutics wants to leverage the same technology that powered COVID-19 vaccines to treat neurological disorders like Alzheimer’s and Parkinson’s disease.

Spun out of the University of British Columbia (UBC), the pre-clinical biotech startup claims that it has already demonstrated an ability to effectively deliver multiple proteins to rodents’ brains, a step on the path to treating brain diseases. This is a longstanding challenge thanks to the restrictive blood-brain barrier (BBB).

Now, armed with $1.4 million CAD in seed funding, CereCura plans to validate the therapeutic efficacy of its lead drug candidate in rodents before proving it can deliver those same proteins to the brains of larger animals.

“We’re seeing this as something that will change the way we t

See Full Page